An anticancer agent icaritin induces sustained activation of the extracellular signal-regulated kinase (ERK) pathway and inhibits growth of breast cancer cells

European Journal of Pharmacology

Volumn 658, Issue 2-3, 2011, Pages 114-122

  Guo, YuMing ^a,b   Zhang, XinTian ^a   Meng, Jun ^a,c   Wang, Zhao Yi ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Beijing Shenogen Biomedical Co Ltd   (China)

^c ZHENGZHOU UNIVERSITY OF LIGHT INDUSTRY   (China)

Author keywords

Apoptosis; Breast cancer stem cells; Cell cycle arrest; ERK; Icaritin

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN B; CYCLIN DEPENDENT KINASE 1; DIMETHYL SULFOXIDE; ICARITIN; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROPIDIUM IODIDE; PROTEIN BCL 2; PROTEIN TYROSINE PHOSPHATASE; TAMOXIFEN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER STEM CELL; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL STRAIN; CELL STRAIN MCF 7; CELL STRAIN MDA MB 453; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; G2 PHASE; HUMANS; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION;

EID: 79953778810     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.02.005     Document Type: Article

References (38)

1. Adachi, T., Kar, S., Wang, M., Carr, B.I., 2002. Transient and sustained ERK phosphorylation and nuclear translocation in growth control. J. Cell. Physiol. 192, 151-159.
2. Chang, L., Karin, M., 2001. Mammalian MAP kinase signalling cascades. Nature 410, 37-40. (Pubitemid 32225829)
3. Charafe-Jauffret, E., Ginestier, C., Iovino, F., Wicinski, J., Cervera, N., Finetti, P., Hur, M.H., Diebel, M.E., Monville, F., Dutcher, J., Brown, M., Viens, P., Xerri, L., Bertucci, F., Stassi, G., Dontu, G., Birnbaum, D., Wicha, M.S., 2009. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 69, 1302-1313.
4. Chen, J.R., Plotkin, L.I., Aguirre, J.I., Han, L., Jilka, R.L., Kousteni, S., Bellido, T., Manolagas, S.C., 2005. Transient versus sustained phosphorylation and nuclear accumulation of ERKs underlie anti-versus pro-apoptotic effects of estrogens. J. Biol. Chem. 280, 4632-4638.
5. Cole, M.P., Jones, C.T., Todd, I.D., 1971. A new anti-oestrogenic agent in late breast cancer: an early clinical appraisal of ICI46474. Br. J. Cancer 25, 270-275.
6. Fillmore, C.M., Kuperwasser, C., 2008. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 10, R25.
7. Ginestier, C., Hur, M.H., Charafe-Jauffret, E., Monville, F., Dutcher, J., Brown, M., Jacquemier, J., Viens, P., Kleer, C.G., Liu, S., Schott, A., Hayes, D., Birnbaum, D., Wicha, M.S., Dontu, G., 2007. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1, 555-567. (Pubitemid 350056407)
8. Hambardzumyan, D., Squatrito, M., Holland, E.C., 2006. Radiation resistance and stem-like cells in brain tumors. Cancer Cell 10, 454-456. (Pubitemid 44854752)
9. Hartwell, L.H., Kastan, M.B., 1994. Cell cycle control and cancer. Science 266, 1821-1828.
10. He, J., Wang, Y., Duan, F., Jiang, H., Chen, M.F., Tang, S.Y., 2010. Icaritin induces apoptosis of HepG2 cells via the JNK1 signaling pathway independent of the estrogen receptor. Planta Med. 76, 1834-1839.
11. Huang, J., Yuan, L., Wang, X., Zhang, T.L., Wang, K., 2007a. Icaritin and its glycosides enhance osteoblastic, but suppress osteoclastic, differentiation and activity in vitro. Life Sci. 81, 832-840. (Pubitemid 47337100)
12. Huang, X., Zhu, D., Lou, Y., 2007b. A novel anticancer agent, icaritin, induced cell growth inhibition, G1 arrest and mitochondrial transmembrane potential drop in human prostate carcinoma PC-3 cells. Eur. J. Pharmacol. 564, 26-36.
13. Kim, B.W., Lee, E.R., Min, H.M., Jeong, H.S., Ahn, J.Y., Kim, J.H., Choi, H.Y., Choi, H., Kim, E.Y., Park, S.P., Cho, S.G., 2008. Sustained ERK activation is involved in the kaempferol-induced apoptosis of breast cancer cells and is more evident under 3-D culture condition. Cancer Biol. Ther. 7, 1080-1089.
14. Kurokawa, H., Nishio, K., Fukumoto, H., Tomonari, A., Suzuki, T., Saijo, N., 1999. Alteration of caspase-3 (CPP32/Yama/apopain) in wild-type MCF-7 breast cancer cells. Oncol. Rep. 6, 33-37.
15. Lewis, J.S., Jordan, V.C., 2005. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat. Res. 591, 247-263.
16. Liu, S., Dontu, G., Wicha, M.S., 2005. Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res. 7, 86-95. (Pubitemid 40704127)
17. Mandal, D., Moitra, P.K., Saha, S., Basu, J., 2002. Caspase 3 regulates phosphatidylserine externalization and phagocytosis of oxidatively stressed erythrocytes. FEBS Lett. 513, 184-188. (Pubitemid 34251261)
18. Mandlekar, S., Kong, A.N., 2001. Mechanisms of tamoxifen-induced apoptosis. Apoptosis 6, 469-477. (Pubitemid 33078758)
19. Marshall, C.J., 1995. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80, 179-185.
20. Molinari, M., 2000. Cell cycle checkpoints and their inactivation in human cancer. Cell Prolif. 33, 261-274.
21. Muss, H.B., 1992. Endocrine therapy for advanced breast cancer: a review. Breast Cancer Res. Treat. 21, 15-26.
22. Normanno, N., Di Maio, M., De Maio, E., De Luca, A., de Matteis, A., Giordano, A., Perrone, F., 2005. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr. Relat. Cancer 12, 721-747.
23. Patel, T., Gores, G.J., Kaufmann, S.H., 1996. The role of proteases during apoptosis. FASEB J. 10, 587-597. (Pubitemid 26141170)
24. Perry, R.R., Kang, Y., Greaves, B., 1995. Effects of tamoxifen on growth and apoptosis of estrogen-dependent and -independent human breast cancer cells. Ann. Surg. Oncol. 2, 238-245.
25. Platanias, L.C., 2003. Map kinase signaling pathways and hematologic malignancies. Blood 101, 4667-4679. (Pubitemid 36857719)
26. Ramos, J.W., 2008. The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells. Int. J. Biochem. Cell Biol. 40, 2707-2719.
27. Recchia, I., Rucci, N., Funari, A., Migliaccio, S., Taranta, A., Longo, M., Kneissel, M., Susa, M., Fabbro, D., Teti, A., 2004. Reduction of c-Src activity by substituted 5,7-diphenylpyrrolo[2,3-d]-pyrimidines induces osteoclast apoptosis in vivo and in vitro. Involvement of ERK1/2 pathway. Bone 34, 65-79. (Pubitemid 38142435)
28. Robinson, M.J., Cobb, M.H., 1997. Mitogen-activated protein kinase pathways. Curr. Opin. Cell Biol. 9, 180-186.
29. Roux, P.P., Blenis, J., 2004. ERK and p38MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol. Mol. Biol. Rev. 68, 320-344.
30. Shafee, N., Smith, C.R., Wei, S., Kim, Y., Mills, G.B., Hortobagyi, G.N., Stanbridge, E.J., Lee, E.Y., 2008. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res. 68, 3243-3250.
31. Stanciu, M., Wang, Y., Kentor, R., Burke, N., Watkins, S., Kress, G., Reynolds, I., Klann, E., Angiolieri, M.R., Johnson, J.W., DeFranco, D.B., 2000. Persistent activation of ERK contributes to glutamate-induced oxidative toxicity in a neuronal cell line and primary cortical neuron cultures. J. Biol. Chem. 275, 12200-12206.
32. Traverse, S., Gomez, N., Paterson, H., Marshall, C., Cohen, P., 1992. Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells. Comparison of the effects of nerve growth factor and epidermal growth factor. Biochem. J. 288 (Pt 2), 351-355.
33. Wang, Z.Q., Lou, Y.J., 2004. Proliferation-stimulating effects of icaritin and desmethylicaritin in MCF-7 cells. Eur. J. Pharmacol. 504, 147-153.
34. Wang, Z., Zhang, X., Wang, H., Qi, L., Lou, Y., 2007. Neuroprotective effects of icaritin against beta amyloid-induced neurotoxicity in primary cultured rat neuronal cells via estrogen-dependent pathway. Neuroscience 145, 911-922. (Pubitemid 46441658)
35. Wo, Y.B., Zhu, D.Y., Hu, Y., Wang, Z.Q., Liu, J., Lou, Y.J., 2008. Reactive oxygen species involved in prenylflavonoids, icariin and icaritin, initiating cardiac differentiation of mouse embryonic stem cells. J. Cell. Biochem. 103, 1536-1550.
36. Xiao, D., Srivastava, S.K., Lew, K.L., Zeng, Y., Hershberger, P., Johnson, C.S., Trump, D.L., Singh, S.V., 2003. Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits proliferation of human prostate cancer cells by causing G2/M arrest and inducing apoptosis. Carcinogenesis 24, 891-897. (Pubitemid 36748905)
37. Zhang, G., Qin, L., Sheng, H., Wang, X.L., Wang, Y.X., Yeung, D.K., Griffith, J.F., Yao, X.S., Xie, X.H., Li, Z.R., Lee, K.M., Leung, K.S., 2009. A novel semisynthesized small molecule icaritin reduces incidence of steroid-associated osteonecrosis with inhibition of both thrombosis and lipid-deposition in a dose-dependent manner. Bone 44, 345-356.
38. Zhu, D.Y., Lou, Y.J., 2005. Inducible effects of icariin, icaritin, and desmethylicaritin on directional differentiation of embryonic stem cells into cardiomyocytes in vitro. Acta Pharmacol. Sin. 26, 477-485.